Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | STAT3 | P40763 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15809167 | 0.67 | CA1 (0.33) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL62430 | 0.64 | CA9 (0.46) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL31003510 | 0.64 | CA9 (0.46) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL4303151 | 0.62 | CA1 (0.41) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL1451128 | 0.62 | CA1 (0.41) | CA1CA2CA9MEN1NPC1 | |
| SCHEMBL10855633 | 0.60 | CA2 (0.35) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL9490386 | 0.60 | — | — | |
| SCHEMBL10816373 | 0.60 | CA1 (0.34) | CA1CA2CA9CA12MEN1 | |
| Methoxymethane SCHEMBL10856175 | 0.58 | CA9 (0.41) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL19744948 | 0.58 | GPR3 (0.48) | CA1CA2CA9CA12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | claimed |
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | claimed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | claimed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | claimed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | claimed |
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | disclosed |
| WO-2024005197-A1 | SOLID DISPERSION, PHARMACEUTICAL PREPARATION CONTAINING SOLID DISPERSION, AND METHODS RESPECTIVELY FOR PRODUCING THESE PRODUCTS | 日本新薬株式会社 | 2024-01-04 | — | — | WO | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20230040402-A1 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040402-A1 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | MPEG1, CD274, PDCD1 | CA1 2545/4885CA2 2574/4885CA9 383/4885 |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | CA1 3990/4885CA2 3851/4885CA9 4244/4885 |
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | CA1 355/4885CA2 827/4885CA9 658/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | CA1 2940/4885CA2 3615/4885CA9 1186/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | CA1 2961/4885CA2 3401/4885CA9 3195/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | CA1 3818/4885CA2 549/4885CA9 1343/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | CA1 2961/4885CA2 3401/4885CA9 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.